DDrare: Database of Drug Development for Rare Diseases

Ursodeoxycholic acid combination of immunosuppressive agents (DrugBank: Ursodeoxycholic acid)

2 diseases

ID	Disease name (Link within this page)	Number of trials
93	Primary biliary cholangitis [Primary biliary cirrhosis (~Mar 2017)]	1
95	Autoimmune hepatitis	1

93. Primary biliary cholangitis [Primary biliary cirrhosis (~Mar 2017)] [ 230 clinical trials, 215 drugs, (DrugBank: 51 drugs), 34 drug target genes, 107 drug target pathways]

Searched query = "Primary biliary cholangitis", "Primary biliary cirrhosis", "PBC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 230 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02936596 (ClinicalTrials.gov)	December 2016	15/10/2016	Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome	Biochemical Response of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Induced by Ursodeoxycholic Acid Only or Combination Therapy of Immunosuppressive Agents	Hepatitis, Autoimmune;Cholangitis;Liver Cirrhosis, Biliary;Cholestasis	Drug: Ursodeoxycholic acid combination of immunosuppressive agents;Drug: Ursodeoxycholic Acid	Xiaoli Fan	NULL	Recruiting	18 Years	75 Years	All	53	N/A	China

95. Autoimmune hepatitis [ 44 clinical trials, 57 drugs, (DrugBank: 26 drugs), 18 drug target genes, 108 drug target pathways]

Searched query = "Autoimmune hepatitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 44 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02936596 (ClinicalTrials.gov)	December 2016	15/10/2016	Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome	Biochemical Response of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Induced by Ursodeoxycholic Acid Only or Combination Therapy of Immunosuppressive Agents	Hepatitis, Autoimmune;Cholangitis;Liver Cirrhosis, Biliary;Cholestasis	Drug: Ursodeoxycholic acid combination of immunosuppressive agents;Drug: Ursodeoxycholic Acid	Xiaoli Fan	NULL	Recruiting	18 Years	75 Years	All	53	N/A	China